WEBINAR SERIES: Modern medicines series SGLT2 Inhibitors: What we need to know

About the series

Over 3 programmes, Professor Cliff Bailey and colleagues will be providing concise evidence-based guidance to contemporary medications and their application in daily care.

The aim: To assess the clinical evidence and opportunities offered by sodium-glucose co-transporter-2 (SGLT2) inhibitors in the management of type 2 diabetes and its cardio-renal complications.

Objectives:

  • Understand the mode of action of SGLT2 inhibitors to inhibit the reabsorption of filtered glucose by the kidney
  • Appreciate the metabolic effects of SGLT2 inhibitors on glycaemic control and body weight control in the management of type 2 diabetes
  • Assess the effects of SGLT2 inhibitors on cardiac and vascular function
  • Evaluate the role of SGLT2 inhibitors in the management of blood pressure, heart failure and atherosclerotic disease with and without type 2 diabetes
  • Examine the emerging evidence for reno-protective effects of SGLT2 inhibitors
  • Consider the potential opportunities for SGLT2 inhibitors in the management of diabetic kidney disease

Included in each programme:

  • A one hour webinar including a live Q&A discussion
  • Downloadable slides to print off and keep
  • A downloadable factsheet summarising the guidance
  • A case study based CPD learning module with certificate upon completion

The series will complete with 2 further update webinars later in the year, dates and times tbc.

 

Programme 3 – SGLT2 inhibitors and the kidney
Tuesday 9th March, 19.00

Speaker: Professor Cliff Bailey

Reno-protective effects of SGLT2 inhibitors

  1. Kidney disease in type 2 diabetes
  2. SGLT2 inhibitors and glomerular filtration rate
  3. SGLT2 inhibitors reduced albuminuria
  4. Reno-protective mechanisms of SGLT2 inhibitors

Speaker: Dr Pam Brown

SGLT2 inhibitors in the management diabetic kidney disease

  1. Slow decline in glomerular filtration rate
  2. Reduce albuminuria 
  3. Delay progression of CKD without diabetes
  4. Value in prevention and treatment of diabetic kidney disease

The series will complete with 2 further update webinars later in the year, dates and times tbc.

 

Your programme presenters

Professor Cliff Bailey

Emeritus Professor of Clinical Science, Aston University, Birmingham

Professor Vinod Patel

Professor, Diabetes and Clinical Skills,
Warwick Medical School. Honorary
Consultant in Endocrinology and Diabetes, George Eliot Hospital, Nuneaton
Dr Martin Hadley-Brown

FRCGP,
Hughes Hall, University of Cambridge

 Dr Pam Brown

GP, SA1 Medical Practice,
Swansea

Plus each programme has

  • downloadable slides to print off and keep
  • a downloadable factsheet of practical guidance
  • an interactive CPD learning module with certificate upon completion

You can now watch Programme 1 & 2 on-demand. If you cannot attend any of the live broadcasts, the webinars will be available on-demand 24 hours after the event.

 

Programme 1 – Understanding SGLT2 inhibition
Tuesday 9th February, 19.00

Speaker: Professor Cliff Bailey

Type 2 diabetes and SGLT2 inhibitors in context

  1. Type 2 diabetes as a metabolic and cardio-renal disease
  2. Different glucose-lowering therapies
  3. The SGLT2 inhibitor class
  4. Mechanism of SGLT2 inhibition

Speaker: Professor Vinod Patel

Managing glycaemic control and body weight

  1. Glucose control and weight control in RCTs
  2. Real world evidence of efficacy 
  3. Tolerability and safety profiles
  4. Positioning in treatment algorithms for type 2 diabetes

Click below to watch the webinar on-demand.

Watch on-demand now Request a password

This webinar is password protected, you will have received the password in the invitation email. If you don’t have a password please feel free to email us at: admin@issuesandanswers.org.

 

Programme 2 – SGLT2 inhibitors and the heart
Tuesday 23rd February, 19.00

Speaker: Professor Cliff Bailey

Effects of SGLT2 inhibitors on cardiovascular function

  1. Cardiovascular disease in type 2 diabetes
  2. SGLT2 inhibitors lower blood pressure
  3. SGLT2 inhibitors reduced heart failure risk
  4. Mechanisms of SGLT2 inhibitors on heart and circulation

Speaker: Dr Martin Hadley-Brown

Role of SGLT2 inhibitors in the management of CV disease

  1. Improve BP control independently of other antihypertensives
  2. Reduce risk of new onset or worsening heart failure 
  3. May benefit atherosclerotic cardiovascular disease
  4. Positioned in algorithms for type 2 diabetes by CV effects

Click below to watch the webinar on-demand.

Watch on-demand now Request a password

This webinar is password protected, you will have received the password in the invitation email. If you don’t have a password please feel free to email us at: admin@issuesandanswers.org.

 

Don’t forget to share this programme with a colleague click here

 This webinar is supported by Boehringer Ingelheim through an unrestricted educational grant

 

 

 

The content, opinions and statements made in this webinar are those of the presenters and do not necessarily reflect the views of the supporters, editors or editorial board and no liability is accepted for the consequences of any misleading or inaccurate information.